Publikation: Application of the 3Rs Principles in the Development of Pharmaceutical Generics
Dateien
Datum
Autor:innen
Herausgeber:innen
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
DOI (zitierfähiger Link)
Internationale Patentnummer
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Sammlungen
Core Facility der Universität Konstanz
Titel in einer weiteren Sprache
Publikationstyp
Publikationsstatus
Erschienen in
Zusammenfassung
Although the 3Rs are broadly applied in nonclinical testing, a better appreciation of the 3Rs is needed in the field of differentiated or value-added pharmaceutical generics because the minor changes in formulation, dosage form, indication, and application route often do not require additional safety testing. The US FDA and the EU EMA have comprehensive regulations for such drugs based on quality, therapeutic equivalence, and safety guidelines. However, no scientific publications on how the concept of replacement and reduction from 3Rs principles can be applied in the safety assessment of differentiated generics were found in the public domain. In this review, we discuss the application of 3Rs in nonclinical testing requirements for differentiated generics. Practical examples are provided in the form of case studies from regulated markets. We highlight the need to utilize existing data to establish equivalence (differentiated generic vs innovator) in efficacy and safety. The case studies indicate that data requirements from animal experiments have been reduced to a large extent in some major markets without compromising quality and safety. In this context, we also highlight the problem that on a global scale, a true reduction of animal experiments will only be achieved when all countries adopt similar practices.
Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
Schlagwörter
Konferenz
Rezension
Zitieren
ISO 690
VICHARE, Abhijit S., Sushant U. KAMATH, Marcel LEIST, A. Wallace HAYES, Brinda MAHADEVAN, 2021. Application of the 3Rs Principles in the Development of Pharmaceutical Generics. In: Regulatory Toxicology and Pharmacology : RTP. Elsevier. 2021, 125, 105016. ISSN 0273-2300. eISSN 1096-0295. Available under: doi: 10.1016/j.yrtph.2021.105016BibTex
@article{Vichare2021-10Appli-54418, year={2021}, doi={10.1016/j.yrtph.2021.105016}, title={Application of the 3Rs Principles in the Development of Pharmaceutical Generics}, volume={125}, issn={0273-2300}, journal={Regulatory Toxicology and Pharmacology : RTP}, author={Vichare, Abhijit S. and Kamath, Sushant U. and Leist, Marcel and Hayes, A. Wallace and Mahadevan, Brinda}, note={Article Number: 105016} }
RDF
<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/54418"> <dc:contributor>Mahadevan, Brinda</dc:contributor> <dc:contributor>Vichare, Abhijit S.</dc:contributor> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-07-27T13:56:24Z</dcterms:available> <dcterms:title>Application of the 3Rs Principles in the Development of Pharmaceutical Generics</dcterms:title> <foaf:homepage rdf:resource="http://localhost:8080/"/> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dc:creator>Mahadevan, Brinda</dc:creator> <dc:language>eng</dc:language> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/54418"/> <dc:creator>Leist, Marcel</dc:creator> <dc:creator>Vichare, Abhijit S.</dc:creator> <dc:contributor>Kamath, Sushant U.</dc:contributor> <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dc:creator>Hayes, A. Wallace</dc:creator> <dc:contributor>Leist, Marcel</dc:contributor> <dc:contributor>Hayes, A. Wallace</dc:contributor> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-07-27T13:56:24Z</dc:date> <dc:creator>Kamath, Sushant U.</dc:creator> <dc:rights>terms-of-use</dc:rights> <dcterms:abstract xml:lang="eng">Although the 3Rs are broadly applied in nonclinical testing, a better appreciation of the 3Rs is needed in the field of differentiated or value-added pharmaceutical generics because the minor changes in formulation, dosage form, indication, and application route often do not require additional safety testing. The US FDA and the EU EMA have comprehensive regulations for such drugs based on quality, therapeutic equivalence, and safety guidelines. However, no scientific publications on how the concept of replacement and reduction from 3Rs principles can be applied in the safety assessment of differentiated generics were found in the public domain. In this review, we discuss the application of 3Rs in nonclinical testing requirements for differentiated generics. Practical examples are provided in the form of case studies from regulated markets. We highlight the need to utilize existing data to establish equivalence (differentiated generic vs innovator) in efficacy and safety. The case studies indicate that data requirements from animal experiments have been reduced to a large extent in some major markets without compromising quality and safety. In this context, we also highlight the problem that on a global scale, a true reduction of animal experiments will only be achieved when all countries adopt similar practices.</dcterms:abstract> <dcterms:issued>2021-10</dcterms:issued> </rdf:Description> </rdf:RDF>